Pathology steered stratification network for subtype identification in Alzheimer's disease

Abstract

AbstractBackgroundAlzheimer's disease (AD) is a heterogeneous, multifactorial neurodegenerative disorder characterized by three neurobiological factors beta‐amyloid, pathologic tau, and neurodegeneration. There are no effective treatments for AD at a late stage, urging for early detection and prevention. However, existing statistical inference approaches in neuroimaging studies of AD subtype identification do not take into account the pathological domain knowledge, which could lead to ill‐posed results that are sometimes inconsistent with the essential neurological principles.PurposeIntegrating systems biology modeling with machine learning, the study aims to assist clinical AD prognosis by providing a subpopulation classification in accordance with essential biological principles, neurological patterns, and cognitive symptoms.MethodsWe propose a novel pathology steered stratification network (PSSN) that incorporates established domain knowledge in AD pathology through a reaction‐diffusion model, where we consider non‐linear interactions between major biomarkers and diffusion along the brain structural network. Trained on longitudinal multimodal neuroimaging data, the biological model predicts long‐term evolution trajectories that capture individual characteristic progression pattern, filling in the gaps between sparse imaging data available. A deep predictive neural network is then built to exploit spatiotemporal dynamics, link neurological examinations with clinical profiles, and generate subtype assignment probability on an individual basis. We further identify an evolutionary disease graph to quantify subtype transition probabilities through extensive simulations.ResultsOur stratification achieves superior performance in both inter‐cluster heterogeneity and intra‐cluster homogeneity of various clinical scores. Applying our approach to enriched samples of aging populations, we identify six subtypes spanning AD spectrum, where each subtype exhibits a distinctive biomarker pattern that is consistent with its clinical outcome.ConclusionsThe proposed PSSN (i) reduces neuroimage data to low‐dimensional feature vectors, (ii) combines AT[N]‐Net based on real pathological pathways, (iii) predicts long‐term biomarker trajectories, and (iv) stratifies subjects into fine‐grained subtypes with distinct neurological underpinnings. PSSN provides insights into pre‐symptomatic diagnosis and practical guidance on clinical treatments, which may be further generalized to other neurodegenerative diseases.